IL1B and metabolic syndrome: Furthermore, in a recent clinical trial evaluating the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) administration in a group of patients with type 2 diabetes and dyslipidemia, a significant reduction in plasmatic IL-1β and TNF-α levels was observed after 6 months of treatment with either semaglutide or dulaglutide [39].